Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push
by 
Sanofi has agreed to acquire Vigil Neuroscience in a $470m deal, nearly a year after investing an initial $40m in the company. The deal will see Sanofi acquire all outstanding common shares of US-based Vigil for $8 per share in cash at closing.
Although Vigil has two candidates in its pipeline, Sanofi’s buyout centred around the potential of VG-3927. Indeed, Vigil’s other programme – the fully human monoclonal antibody iluzanebart dubbed VGL101 – is not part of the acquisition and will return to its original licensor, Amgen.
Sanofi has not hidden its high regard for VG-3927, with the $40m investment made in June 2024 giving the French drugmaker the exclusive right of first negotiation regarding its licensing. With the buyout of Vigil, Sanofi now has full control of VG-3927, including research, development, manufacturing, and commercialisation duties.
The companies are expected to close the transaction in the third quarter of 2025. Sanofi said the transaction will not affect its 2025 financial outlook. The acquisition would give Sanofi, one of the world’s largest vaccine makers, control over Vigil’s VG-3927, an oral drug being prepared for a potential treatment in Alzheimer’s.
Visit our upcoming pharma conferences – https://virtueinsight.com/upcoming-conferences/
